Short Description
Goserelina 3.6 Injection is a hormone therapy medicine containing goserelin acetate, a gonadotropin-releasing hormone (GnRH) agonist. It is used in the treatment of certain hormone-sensitive cancers, including prostate and breast cancer, as well as conditions such as endometriosis. It works by reducing the production of sex hormones, including testosterone and oestrogen.
What Is Goserelina 3.6 Injection?
Goserelina 3.6 Injection contains 3.6 mg of goserelina as goserelin acetate. It is a GnRH agonist supplied as a slow-release biodegradable implant in a pre-filled syringe for administration under the skin.
The medicine works by suppressing the release of hormones that stimulate the production of testosterone and oestrogen. This reduction in hormone levels helps manage certain hormone-dependent conditions.
Goserelina is generally administered at 28-day intervals, although the duration of treatment depends on the condition being treated and the healthcare professional's recommendation.
Uses
Goserelina 3.6 Injection may be prescribed to:
Prostate cancer: Treat advanced or locally advanced prostate cancer by reducing testosterone production.
Breast cancer: Manage certain hormone receptor-positive breast cancers in premenopausal and perimenopausal women.
Endometriosis: Reduce endometriosis-related pain and the activity of endometrial-like tissue outside the uterus.
Uterine fibroids: Help improve anaemia associated with fibroids before surgery, generally alongside iron therapy.
Endometrial thinning: Reduce the thickness of the uterine lining before certain surgical procedures, such as endometrial ablation.
Assisted reproduction: Suppress pituitary activity as part of selected fertility treatment protocols.
Approved uses may vary depending on the country and the specific product information. The appropriate treatment and dose should be determined by a healthcare professional.
How Does Goserelina Work?
Goserelina works by acting on GnRH receptors in the pituitary gland, which controls the release of hormones involved in reproductive function.
Initially, it stimulates these receptors, causing a temporary increase in certain hormone levels. With continued treatment, the receptors become less responsive, reducing the release of luteinising hormone (LH) and follicle-stimulating hormone (FSH).
This subsequently reduces testosterone production in men and oestrogen production in premenopausal women. Lower levels of these hormones help control hormone-sensitive cancers and certain gynaecological conditions.
The time needed to achieve the intended hormonal effect varies depending on the condition and individual response.
How to Take Goserelina 3.6 Injection
Take Goserelina 3.6 Injection exactly as prescribed by your healthcare professional.
Administration: The medicine is administered as a subcutaneous implant injection, usually into the front of the abdominal wall below the navel.
Frequency: The standard 3.6 mg formulation is generally administered once every 28 days.
Administration method: A doctor or appropriately trained healthcare professional should administer the injection using the supplied device and recommended technique.
Treatment schedule: Attend scheduled appointments to maintain the prescribed treatment interval.
Missed appointment: Contact your healthcare professional as soon as possible if you miss an appointment. Do not attempt to administer the implant yourself.
Treatment changes: Do not stop treatment, change the injection schedule or delay subsequent doses without consulting your healthcare professional.
The exact treatment duration depends on the medical condition being treated.
Important Safety Information
Before starting Goserelina 3.6 Injection, tell your doctor or pharmacist about your medical history and all medicines, supplements and herbal products you use.
Medical conditions requiring particular attention include:
Osteoporosis: Goserelin may reduce bone mineral density, increasing the risk of weakened bones and fractures.
Diabetes: The medicine may affect blood glucose levels, particularly in men receiving treatment for prostate cancer.
Heart conditions: Patients with existing cardiovascular disease or risk factors may require appropriate monitoring.
Depression: Goserelin may cause or worsen depression, including in patients with a previous history of mood disorders.
Heart rhythm problems: The medicine may prolong the QT interval, particularly in patients with existing risk factors.
Urinary obstruction or spinal cord compression: Men with advanced prostate cancer may experience temporary worsening of symptoms when treatment is initiated.
Bleeding disorders: Extra care is required in patients with a low body mass index or those receiving anticoagulant treatment because of the risk of injection-site bleeding or injury.
Medicine interactions:
Particular attention is required when Goserelina is used alongside:
Medicines that prolong the QT interval, including certain antiarrhythmics, antipsychotics and antibiotics.
Other medicines used in breast cancer treatment, such as aromatase inhibitors, tamoxifen or CDK4/6 inhibitors, where combination treatment requires appropriate monitoring.
Not all medicines interact directly with goserelin, but some combinations may require additional precautions or monitoring. Check all possible interactions with your doctor or pharmacist before starting treatment.
Pregnancy & Breastfeeding
Pregnancy: Goserelina is generally not recommended during pregnancy because it may affect pregnancy development and increase the risk of pregnancy loss. Pregnancy should be excluded before treatment when appropriate. Women who could become pregnant should discuss effective non-hormonal contraception with their healthcare professional during treatment. Specific prescribing exceptions may apply in certain advanced breast cancer treatment settings.
Breastfeeding: Goserelina is generally not recommended during breastfeeding. It is not known whether goserelin passes into human breast milk, and potential risks to the nursing infant cannot be excluded.
Speak with your doctor before starting treatment if you are pregnant, planning a pregnancy or breastfeeding.
Side Effects
Like all medicines, Goserelina 3.6 Injection can cause side effects, although not everyone experiences them.
Commonly reported side effects include:
Hot flushes and excessive sweating.
Headache.
Acne and other skin changes.
Mood changes or depression.
Reduced sexual desire (libido).
Vaginal dryness or changes in menstrual periods in women.
Erectile dysfunction and reduced sexual function in men.
Pain, bruising or discomfort at the injection site.
Seek prompt medical attention if you experience signs of a serious allergic reaction, severe skin reactions such as blistering or peeling, sudden severe back pain accompanied by weakness or numbness, difficulty passing urine, or symptoms suggesting significant changes in blood glucose levels.
This is not a complete list of side effects or warnings. Please refer to the product packaging and patient information leaflet supplied with your medicine for complete information and speak with your doctor or pharmacist if you have concerns.
Storage
Store Goserelina 3.6 Injection according to the instructions shown on the original product packaging.
Keep the medicine in its original sealed packaging until it is ready for administration.
Protect it from unsuitable storage conditions, including excessive heat and moisture.
Follow the manufacturer-specific storage temperature and light-protection instructions.
Keep all medicines out of reach of children.
Do not use the medicine after its stated expiry date.
Do not use the product if its packaging is damaged or the implant appears compromised.
Storage requirements may vary between manufacturers and product presentations. Always follow the instructions supplied with the specific product.